Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery

3530 Background: Bevacizumab [Avastin (BV)] is a humanized monoclonal antibody directed against vascular endothelial growth factor. A recent randomized, double-blinded, Phase III trial showed that addition of Avastin to chemotherapy (bolus irinotecan, 5-FU, leucovorin -IFL) increased survival compared with IFL alone. Antiangiogenic therapy has previously shown delay in wound healing in preclinical models. Therefore, we undertook an analysis of wound healing in subjects receiving BV plus bolus IFL and BV plus 5-FU/LV versus those that received bolus IFL alone. Methods: Wound healing and bleeding complications were analyzed in subjects who underwent primary cancer surgery (i.e., colonic or rectal resection to remove tumor) within 28–60 days of starting study treatment. Sixty-day post-operative adverse events reported as abnormal healing, wound dehiscence, delayed wound healing, bowel perforation, fistula, abscess, and hemorrhage were studied. Results: A total of 150 subjects receiving BV plus bolus IFL and ...